Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

NCT06259669 · clinicaltrials.gov ↗

RECRUITING

Status

958

Enrollment

INDUSTRY

Sponsor class

Conditions

Pregnancy Related
Atopic Dermatitis

Interventions

DRUG: Ruxolitinib Cream

Sponsor

Incyte Corporation